Breaking News, Collaborations & Alliances

Astellas Completes Iveric Bio Acquisition

Developer of treatments for retinal diseases becomes Astellas' wholly owned subsidiary.

Astellas Pharma Inc. has completed the acquisition of IVERIC bio, Inc., a biopharmaceutical company, through its indirect wholly owned subsidiary Berry Merger Sub, Inc. Iveric Bio is now Astellas’ wholly owned subsidiary. Iveric Bio is an innovative biopharmaceutical company focused on the discovery and development of treatments for retinal diseases with significant unmet medical needs. “We are very pleased to welcome Iveric Bio and its highly experienced professionals in the o...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters